lomustine

P2, N=350, Active, not recruiting, Actuate Therapeutics Inc. | Trial completion date: Jan 2026 --> Jun 2026 | Trial primary completion date: Jan 2025 --> Jun 2026

P2/3, N=2250, Recruiting, Global Coalition for Adaptive Research | N=1280 --> 2250

Based on ex vivo drug sensitivity testing, lomustine was initiated as rescue chemotherapy, achieving a second complete remission...Key clinical message: This case highlights the fact that progression from primary mediastinal to multicentric lymphoma may be associated with a poor prognosis in dogs. Radiation therapy demonstrated potential efficacy and warrants further investigation as a treatment option for canine mediastinal lymphoma.

This is the second study associating hypercalcaemia with improved PFS in dogs with non-indolent T-cell lymphoma. Results also suggest prognostic significance of specific CD4/CD8 expression patterns.

P1/2, N=18, Active, not recruiting, Azienda Ospedaliera Universitaria Meyer IRCCS | Not yet recruiting --> Active, not recruiting

As a result, three repurposed drugs were identified as priorities: (i) mefloquine (reference drug: vorasidenib citrate), (ii) clofibric acid (reference drug: carmustine), and armillarisin A (reference drug: lomustine). These results also suggest repurposing candidates for synergistic combinations across different brain tumors. The two applications developed in this work are freely accessible and in the public domain at https://assay.smallmoles.com/escorwin.

P3, N=225, Recruiting, Children's Oncology Group | Trial completion date: Dec 2027 --> Dec 2029 | Trial primary completion date: Dec 2027 --> Dec 2029

P2/3, N=30, Not yet recruiting, Telix Pharmaceuticals (Innovations) Pty Limited

P3, N=265, Active, not recruiting, NRG Oncology | Suspended --> Active, not recruiting

P2, N=45, Active, not recruiting, Children's Oncology Group | Trial completion date: Jun 2027 --> Mar 2028 | Trial primary completion date: Jun 2027 --> Mar 2028

Here the authors report the effects of the off-label use of ivosidenib. The INDIGO trial published evidence of efficacy in using an IDH inhibitor for low-grade gliomas. The role of these drugs in high-grade IDH-mutant gliomas is currently unknown. Further studies are needed to assess their impact on overall and progression-free survival. https://thejns.org/doi/10.3171/CASE25572.

In this discourse, we delineate the case of a 42-year-old male patient diagnosed with IDH-wild-type, MGMT-unmethylated, TERT promoter-mutated, and EGFR-amplified GBM, who manifested an early recurrence during adjuvant temozolomide therapy. Our findings, contextualized within contemporary evidence on re-irradiation (stereotactic radiosurgery/fractionated stereotactic radiation therapy) and combinatorial strategies (BEV with lomustine or irinotecan), underscore the need for further empirical investigation to optimize treatment sequencing in r-GBM. This case emphasizes the necessity for individualized multimodal approaches to improve outcomes in this refractory patient population.